Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Introduction

Serotonin syndrome is a potentially life-threatening condition that can occur as a result of the therapeutic use of serotonergic medications or drug interaction. In this study, we describe two cases of serotonin syndrome-associated hypertensive crisis following linezolid use.

Case Presentation

The first patient was a 52-year-old female who was admitted due to a diabetic foot infection and pneumonia associated with a decreased consciousness level. Serotonin syndrome occurred 24 hours after starting the linezolid use. Resistant hypertension was the main hemodynamic finding. It could not be controlled with amlodipine, valsartan, prazosin, and nitroglycerin infusion. Resistant hypertension and other symptoms of serotonin syndrome were resolved about 48 hours after discontinuation of linezolid use.

The second case was a man with a history of kidney transplant, diabetes, and hypertension. He was admitted to the ICU due to severe COVID-19. Broad-spectrum antibiotics [linezolid, cefepime], and remdesivir was initiated. Following intubation, continuous infusion of fentanyl was used for sedation. Within 24 hours after fentanyl and linezolid initiation, severe agitation, eye clonus, hyperreflexia, hypertension [160-186 /90-110 mmHg], and tachycardia [>100/min] were noted. With the possible diagnosis of serotonin syndrome, fentanyl was discontinued, and morphine was initiated. The patient’s symptoms improved 48 hours after discontinuation of fentanyl.

Conclusion

Both patients had a history of well- controlled hypertension. Hypertensive crisis has occurred after recent or concurrent use of serotonergic agents with linezolid. A thorough evaluation of the patient’s medical history and current condition can help clinicians prevent this syndrome in critically ill patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863299100240507052341
2025-05-01
2025-09-02

  • From This Site

    /content/journals/cds/10.2174/0115748863299100240507052341
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BoyerE.W. ShannonM. The serotonin syndrome.N. Engl. J. Med.2005352111112112010.1056/NEJMra041867 15784664
     [Google Scholar]
  2. TaltonC. Serotonin syndrome/serotonin toxicity.Fed. Pract.2020371045245910.12788/fp.0042 33132683
     [Google Scholar]
  3. WangR.Z. VashisthaV. KaurS. HouchensN.W. Serotonin syndrome: Preventing, recognizing, and treating it.Cleve. Clin. J. Med.2016831181081610.3949/ccjm.83a.15129 27824534
     [Google Scholar]
  4. Sun-EdelsteinC. TepperS.J. ShapiroR.E. Drug-induced serotonin syndrome: A review.Expert Opin. Drug Saf.20087558759610.1517/14740338.7.5.587 18759711
     [Google Scholar]
  5. BartlettD. Drug-induced serotonin syndrome.Crit. Care Nurse2017371495410.4037/ccn2017169 28148614
     [Google Scholar]
  6. SternbachH. The serotonin syndrome.Am. J. Psychiatry1991148670571310.1176/ajp.148.6.705 2035713
     [Google Scholar]
  7. BijlD. The serotonin syndrome.Neth. J. Med.2004629309313 15635814
     [Google Scholar]
  8. RadomskiJ.W. DursunS.M. ReveleyM.A. KutcherS.P. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria.Med. Hypotheses200055321822410.1054/mehy.2000.1047 10985912
     [Google Scholar]
  9. DunkleyE.J.C. IsbisterG.K. SibbrittD. DawsonA.H. WhyteI.M. The hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity.QJM200396963564210.1093/qjmed/hcg109 12925718
     [Google Scholar]
  10. ClemettD. MarkhamA. Linezolid.Drugs200059481582710.2165/00003495‑200059040‑00007
     [Google Scholar]
  11. StalkerD.J. JungbluthG.L. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial.Clin. Pharmacokinet.200342131129114010.2165/00003088‑200342130‑00004 14531724
     [Google Scholar]
  12. ElbarbryF. MoshirianN. Linezolid-associated serotonin toxicity: A systematic review.Eur. J. Clin. Pharmacol.202379787588310.1007/s00228‑023‑03500‑9 37129603
     [Google Scholar]
  13. RubinsteinE. IsturizR. StandifordH.C. Worldwide assessment of linezolid’s clinical safety and tolerability: Comparator-controlled phase III studies.Antimicrob. Agents Chemother.20034761824183110.1128/AAC.47.6.1824‑1831.2003 12760854
     [Google Scholar]
  14. MarcucciC. SandsonN.B. DunlapJ.A. Linezolid-bupropion interaction as possible etiology of severe intermittent intraoperative hypertension?Anesthesiology200410161487148810.1097/00000542‑200412000‑00051 15564978
     [Google Scholar]
  15. AzzouzA. PreussC.V. Linezolid. In: StatPearls.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  16. ScottonW.J. HillL.J. WilliamsA.C. BarnesN.M. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions.Int. J. Tryptophan Res.20191210.1177/1178646919873925 31523132
     [Google Scholar]
  17. GattiM. RaschiE. De PontiF. Serotonin syndrome by drug interactions with linezolid: Clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis.Eur. J. Clin. Pharmacol.202177223323910.1007/s00228‑020‑02990‑1 32901348
     [Google Scholar]
  18. AbadieD. RousseauV. LogerotS. CottinJ. MontastrucJ.L. MontastrucF. Serotonin syndrome.J. Clin. Psychopharmacol.201535438238810.1097/JCP.0000000000000344 26082973
     [Google Scholar]
  19. TaylorJ.J. WilsonJ.W. EstesL.L. Linezolid and serotonergic drug interactions: A retrospective survey.Clin. Infect. Dis.200643218018710.1086/504809 16779744
     [Google Scholar]
  20. BaiAD McKennaS WiseH LoebM GillSS Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants.JAMA Network Open2022512e2247426e10.1001/jamanetworkopen.2022.47426
     [Google Scholar]
  21. MitwallyH SaadMO AlkhiyamiD FahmiAM MahmoudS HmoudEA Risk of serotonin syndrome in acutely ill patients receiving linezolid and opioids concomitantly: A retrospective cohort study.IJID regions20225137010.1016/j.ijregi.2022.09.008
     [Google Scholar]
  22. LodiseT.P. PatelN. RiveraA. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin.Antimicrob. Agents Chemother.201357125901591110.1128/AAC.00921‑13 24041888
     [Google Scholar]
  23. UddinM.F. AlweisR. ShahS.R. Controversies in serotonin syndrome diagnosis and management: A review.J. Clin. Diagn. Res.2017119OE05OE0710.7860/JCDR/2017/29473.10696 29207768
     [Google Scholar]
  24. KimA. A complex case of suspected serotonin syndrome.Am. J. Psychiatry Resid. J.2017810
     [Google Scholar]
  25. Brown How accurate is the hunter serotonin toxicity criteria for diagnosing serotonin syndrome?Evidence-Based Practice2020234252610.1097/EBP.0000000000000612
     [Google Scholar]
  26. Balant-GorgiaA.E. Gex-FabryM. BalantL.P. Clinical pharmacokinetics of clomipramine.Clin. Pharmacokinet.199120644746210.2165/00003088‑199120060‑00002
     [Google Scholar]
  27. AlmasiA. MezaC.E. Doxepin. In: StatPearls.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  28. GarrettP.M. Tramadol overdose and serotonin syndrome manifesting as acute right heart dysfunction.Anaesth. Intensive Care200432457557710.1177/0310057X0403200417 15675220
     [Google Scholar]
  29. KarkowD.C. KauerJ.F. ErnstE.J. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy.J. Clin. Psychopharmacol.201737551852310.1097/JCP.0000000000000751 28796019
     [Google Scholar]
  30. FraerM. KilicF. Serotonin.Hypertension201565594294810.1161/HYPERTENSIONAHA.114.05061 25753975
     [Google Scholar]
  31. EdmonstonD. IsakovaT. WolfM. Plasma serotonin and cardiovascular outcomes in chronic kidney disease.J. Am. Heart Assoc.20231217e02978510.1161/JAHA.123.029785 37609990
     [Google Scholar]
  32. RastogiR. SwarmR.A. PatelT.A. RiouB. Case scenario: Opioid association with serotonin syndrome: Implications to the practitioners.Anesthesiology201111561291129810.1097/ALN.0b013e31823940c0 22037635
     [Google Scholar]
  33. TegederI. LötschJ. GeisslingerG. Pharmacokinetics of opioids in liver disease.Clin. Pharmacokinet.1999371174010.2165/00003088‑199937010‑00002 10451781
     [Google Scholar]
  34. BosilkovskaM. WalderB. BessonM. DaaliY. DesmeulesJ. Analgesics in patients with hepatic impairment: Pharmacology and clinical implications.Drugs201272121645166910.2165/11635500‑000000000‑00000 22867045
     [Google Scholar]
  35. OttM. MannchenJ.K. JamshidiF. WernekeU. Management of severe arterial hypertension associated with serotonin syndrome: A case report analysis based on systematic review techniques.Ther. Adv. Psychopharmacol.2019910.1177/2045125318818814 30886699
     [Google Scholar]
  36. PandyaD. TranM. Verduzco-GutierrezM. Clinical relevance of pharmacogenetics in serotonin syndrome.Case Rep. Psychiatry202020201710.1155/2020/8860434 33101751
     [Google Scholar]
  37. de Castro JulveM. Miralles AlborsP. Ortonobes RoigS. VivesR. FalguerasL. Gómez-ValentM. Hypertensive crisis following the administration of tedizolid: Possible serotonin syndrome.Eur. J. Hosp. Pharm. Sci. Pract.2020271525410.1136/ejhpharm‑2018‑001752 32064090
     [Google Scholar]
/content/journals/cds/10.2174/0115748863299100240507052341
Loading

  • Article Type:     Case Report
Keyword(s): antidepressants; drug interaction; fentanyl; hypertensive crisis; linezolid; Serotonin syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test